2 news items
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
ITCI
7 Aug 24
of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
ITCI
18 Jun 24
of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially
- Prev
- 1
- Next